Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis-Associated Lymphoproliferative Disorders.
Yoshihiko HoshidaAtsuko TsujiiShiro OhshimaYukihiko SaekiMasato YagitaTomoya MiyamuraMasao KatayamaTomonori KawasakiYasushi HiramatsuHisaji OshimaToshihiko MurayamaShinji HigaKazuya KuraokaFuminori HiranoKenji IchikawaMitsutoshi KurosawaHiroaki SuzukiNoriyuki ChibaTakao SugiyamaYuko MinamiHitoshi NiinoAtsushi IhataIkuo SaitoAkiko MitsuoToshitaka MaejimaAtsuhiro KawashimaHiroshi TsutaniKoichiro TakahiTakahiko KasaiYoko ShinnoYoshiro TachiyamaNorihiro TeramotoKenichi TaguchiShinji NaitoShigeru YoshizawaMasahiro ItoYasuo SuenagaShunsuke MoriShoichi NagakuraNorie YoshikawaMitsuharu NomotoAtsuhisa UedaShouhei NagaokaYukio TsuuraKeigo SetoguchiShoji SugiiAsami AbeToshiaki SugayaHiroyuki SugaharaShigeki FujitaYasuo KunugizaNorishige IizukaRyosuke YoshiharaHiroki YabeTomoaki FujisakiEiichi MoriiMorishige TakeshitaMasakazu SatoKazuyoshi SaitoKiyoshi MatsuiYasuhiko TomitaHiroshi FurukawaShigeto TohmaPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2024)
Antirheumatic drugs administered before LPD onset may influence the clinicopathologic features of RA-LPD, with patterns changing over time. Furthermore, TCZ-only regimens are recommended after LPD onset.